Bioengineered Protein Drugs Market research study provides an extensive information of important participants, such as suppliers, manufacturers, distributors, traders, consumers, investors, etc. Bioengineered Protein Drugs Market study depicts an in-depth analysis on the current status of Bioengineered Protein Drugs market that consists of important types, and end uses. The data type of the Bioengineered Protein Drugs Market study contains market revenue, import, export, progress rate, consumption, etc. Further, the study focuses on the prominent and emerging regional and global trends contributing to the growth of the global Bioengineered Protein Drugs market over the stipulated timeframe.
For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=4440
Pharmaceutical and biotechnological companies are the leading end users in the bioengineered protein drugs market, as these companies constantly strive to increase the exclusivity to their portfolios. Collectively, these end users are projected to account for 53% of the market share by 2025. However, a shift from in-house R&D towards outsourced services is augmenting the importance of contract research organisations as end users in the bioengineered protein drugs market.
Increasing reliance on these organisations for drug discovery portends the growing adoption of bioengineered protein drugs to further improve their efficacy. In addition, governments of developed regions have extended financial aid to reduce the mortality rate, which is further likely to strengthen the pathway for the penetration of bioengineered protein drugs.
For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=4440
Though the overall market movement looks prodigious, an analytical study published by Fact.MR foresees the advent of generic drugs as an impeder to the growth of the global bioengineered protein drugs market.
Key Highlights of Bioengineered Protein Drugs Market
- Patients suffering from cancer continue to remain the target audience of players in the bioengineered protein drugs market. Adoption of bioengineered protein drugs for treatment is projected to increase at a CAGR of around 7% during the forecast period (2020-2025). Also, a spurt in the sales of these drugs is expected, which is likely to be driven by individuals diagnosed with infectious diseases.
For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4440/S
- High costs associated with bioengineered protein drugs, in tandem with their short shelf life, causes reluctance among patients towards their adoption. In addition, increasing development of biosimilar products that cost just 20% of branded drugs is expected to deter revenue potential of the bioengineered protein drugs market during the forecast period.
- Preference for oral route of drug administration for any medication is high among patients, on the back of convenience and ease. However, bioengineered protein drugs are difficult to administer in an oral formulation, on account of gastric acid formed in the stomach, which could impede their adoption rate.
A subject matter expert at Fact.MR opines, “The healthcare industry is experiencing a shift from curative care towards preventive care, which is projected to create more sales prospects for bioengineered protein vaccines over therapeutic proteins.”
For comprehensive insights on this market adoption, ask an analyst here – https://www.factmr.com/connectus/sample?flag=AE&rep_id=4440
Prominent Players Rely on Generic Drugs and Strong Distribution Network
F.Hoffmann-La Roche, AbbVie, and Johnson & Johnson are the leading players, collectively accounting for around 60% share in the global bioengineered protein drugs market. The focal point of these players is on the development of branded drugs to treat myriad rare diseases. A substantial revenue of F.Hoffmann-La Roche is attributable to its blockbuster drugs – Avastin, Rituxan, and Herceptin, specifically developed for the treatment of cancer. Another leading player, AbbVie, holds a dominant position in the bioengineered protein drugs market, on account of its flagship product-Humira-which is considered as a breakthrough product to treat a number of conditions and diseases.
In contrast to the focus of leading players on the development of branded drugs, prominent and emerging players strive to ace the market race through generic formulations. Also, they take measured actions towards strengthening their distribution network to increase the accessibility of their products.
Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape
Rapid Medical Diagnostic Kits Market, Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2021 to 2031: https://www.factmr.com/report/rapid-medical-diagnostic-kits-market
Syringes and Cannulas Market, Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2020 to 2030: https://www.factmr.com/report/2007/syringes-cannulas-market
Lab Automation Market, Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2021 to 2031: https://www.factmr.com/report/lab-automation-market
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583